Ratings Surperformance

Trader
Investor
Global
Quality
ESG MSCI
BBB

Ratings ESG MSCI

Ratings Sinopharm Group Co. Ltd.: Strengths and Weaknesses

  • The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
  • The company presents an interesting fundamental situation from a short-term investment perspective.
Highlights: Sinopharm Group Co. Ltd.
  • The group's high margin levels account for strong profits.
  • The equity is one of the most attractive in the market with regard to earnings multiple-based valuation.
  • The stock, which is currently worth 2026 to 0.11 times its sales, is clearly overvalued in comparison with peers.
  • The company appears to be poorly valued given its net asset value.
  • The company has a low valuation given the cash flows generated by its activity.
  • The company is one of the best yield companies with high dividend expectations.
  • Analysts covering this company mostly recommend stock overweighting or purchase.
  • The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
  • Analyst opinion has improved significantly over the past four months.
Weaknesses: Sinopharm Group Co. Ltd.
  • As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
  • For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
  • Revenue estimates are regularly revised downwards for the current and coming years.

Rating Financials

Sinopharm Group Co. Ltd. SectorHong Kong

Fundamentals

Growth

Revenue growth

EPS growth

FCF growth

Profitability

EBITDA Margin

EBIT Margin

Net Margin

Capital Efficiency

ROA

ROCE

ROE

Financial Health

Gearing

Leverage

Capital Intensity

Balance sheet growth

Long Term balance sheet growth

Long term revenue growth

Long term EPS growth

More ratings

Rating Valuation

Sinopharm Group Co. Ltd. SectorHong Kong

Global Valuation

Enterprise value

EV/Revenue

EV/EBITDA

EV/FCF

Equity Valuation

P/E

PBR

Dividend Yield

EV/EBIT

CAPEX/Revenue

More ratings

Rating Consensus

Sinopharm Group Co. Ltd. SectorHong Kong

Consensus

Analysts' buy/sell recommendations

Analysts' recommendations evolution (1 year)

Analysts' recommendations evolution (4 months)

Analysts' target price

Analysts' target price evolution (1 year)

Analysts' target price evolution (4 months)

Analysts' recommendations evolution (7 days)

Target Price evolution (7 days)

More ratings

Rating Business Predictability

Sinopharm Group Co. Ltd. SectorHong Kong

Visibility

Analysts' coverage

Financial estimates divergence

Analysts' recommendations divergence

Analysts' Target price divergence

Surprise rates

Rating Revisions

Sinopharm Group Co. Ltd. SectorHong Kong

Financial revisions

Revenue revisions (1 year)

Revenue revisions (4 months)

EPS revisions (1 year)

EPS revisions (4 months)

EPS revisions (7 days)

Revenue revisions (7 days)

More ratings

Capi.($) Investor ESG MSCI Fundamentals Financial revisions Global Valuation Visibility Consensus
685.46Cr
BBB
9.32TCr -
AA
- -
4.82TCr -
AAA
- -
2.37TCr
AAA
805Cr
AA
735.76Cr
AA
663.57Cr
BBB
527.33Cr
AAA
365.84Cr
BB
341.35Cr
AA
-
Average 2.06TCr
AA
Weighted average by Cap.
AA
  1. Stock Market
  2. Equities
  3. 1099 Stock
  4. Ratings Sinopharm Group Co. Ltd.